With FDA Support, Sarepta (SRPT) Receives Waiver for Elevidys BLA Fee, Totaling $4.68 Million.
Regulatory Hurdles Eased and PDUFA Fee Waivers
The U.S. Food and Drug Administration (FDA) operates a policy of waiving Prescription Drug User Fee Act (PDUFA) review fees to alleviate the financial burden on small biotech companies and promote the development of innovative new drugs. For fiscal year 2026, the new drug application (NDA) and biologics license application (BLA) submission fees, including clinical data, amount to $4,682,003 (approximately 6.4 billion Korean Won) per application. Sarepta Therapeutics (SRPT) leveraged this system to significantly reduce the development costs of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for Duchenne Muscular Dystrophy (DMD).
Funding Programs to Accelerate Clinical Development
To support clinical development prior to application submission, the FDA also runs the Orphan Products Clinical Trials Grants and Small Business Innovation Research (SBIR) programs. In 2026, the maximum SBIR grant per project is $323,090 for Phase 1 and $2,153,927 for Phase 2, helping to mitigate the risk of running out of cash. This funding enables early-stage biotechs, before securing venture capital (VC), to reliably initiate Phase 1/2 trials.
Post-Approval Exclusivity and Patent Extension Benefits
The FDA also strongly operates post-approval incentive systems that guarantee market exclusivity for new drugs. Treatments that receive Orphan Drug Designation (ODD) are granted seven years of marketing exclusivity from the approval date, protecting against early entry of generics or biosimilars. In addition, the Hatch-Waxman Act provides for patent term restoration, extending the patent life by up to five years to compensate for the time lost during regulatory review.
Changing Competitive Landscape and M&A Synergies with Large Corporations
This FDA policy creates a market environment that encourages large pharmaceutical companies (Big Pharma) to actively acquire the early-stage pipelines of smaller companies to reduce development risk. As seen with Pfizer (PFE), whose DMD pipeline, fordadistrogene movaparvovec, recently failed in Phase 3 trials, smaller companies that receive government incentives become attractive alternatives when the risk of independent development increases. Large corporations can safely acquire proven assets with secured exclusivity, while smaller companies gain an exit opportunity, creating a virtuous cycle of funding throughout the industry.
Impact on Investment and the Job Market
From the perspective of biotech investors and job seekers, the FDA's small business funding system serves as a reliable benchmark for investments that guarantee high returns relative to risk. Companies that secure government grants at the pre-clinical stage have improved financial health, making it easier to attract subsequent institutional investment. As a result, this leads to large-scale hiring of clinical development personnel and regulatory science experts, contributing to the revitalization of the job market.
Compared to competitors such as Pfizer (PFE), which experienced a Phase 3 failure, companies like Sarepta Therapeutics (SRPT) are significantly improving their early R&D financial stability by utilizing BLA review fee waivers of $4,682,003 per application and annual SBIR Phase II grants of up to $2,153,927. From an investor's perspective, the seven-year marketing exclusivity and up to five-year patent term restoration serve as a safety net that maximizes long-term cash flow and M&A value. For researchers and industry professionals, the expected long-term impact includes expanded opportunities for early clinical entry of innovative pipelines and job creation within the rare disease treatment market, which is expected to grow to $300 billion by 2030. Government grant eligibility is directly linked to a company's early survival, making it a key indicator for gauging subsequent investment and technology transfer opportunities.
Source: FDA Drug Approvals (rss)